| Supplemental Table 2: Pharmacokinetics of AN12855 in murine models. | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Mice strain** | **CD-1** | | | **C57Bl/6** | | | | | | **BALB/c (infected)** | |
| **Route-Dose** | **IV-5 mg/kg** | **Oral-10 mg/kg** | | **Oral-10 mg/kg** | | **Oral-25 mg/kg** | | **Oral-50 mg/kg** | | **Oral-10 mg/kg** | **Oral-50 mg/kg** |
| **Number of Mice** | 3 | 3 | | 2 | | 2 | | 2 | | 3 | 3 |
| **Dosing Schedule** | Single dose | Single dose | | QD-4 days | | QD-4 days | | QD-4 days | | QD-3 wk | QD-3 wk |
| | Plasma | Plasma | Lung | Plasma | Lung | Plasma | Lung | Plasma | Lung | Plasma | Plasma |
| **Cmax (µg/mL)** | 6.32 | 1.74 | 1.02 | 5.79 | 0.584 | 12.6 | 1.9 | 14.9 | 3.5 | 8.36 | 61.6 |
| **Ratio Plasma Cmax/Dose** | | | | 0.58 | - | 0.5 | - | 0.3 | | | |
| **Tmax (h)** | | 0.5 | 4 | 0.5 | 5 | 0.5 | 5 | 0.5 | 5 | 0.5 | 0.5 |
| **AUClast (h*µg/mL)** | 14.3 | 15.4 | 10.4 | 17.6 | N/A | 46.8 | N/A | 82.4 | N/A | 28.9 | 192 |
| **AUC0-inf (h*µg/mL)** | 14.4 | 15.5 | - | 19.7 | - | 59 | - | 109 | - | 29 | 192 |
| **Ratio Plasma AUC0-last / Dose** | | | | 1.8 | - | 1.9 | - | 1.6 | | | |
| **Terminal t1/2 (h)** | 3.46 | 3.27 | - | 2.5 | - | 3.52 | - | 3.76 | - | 3.04 | 2.4 |
| | | | | | | | | | | | |
| **CL (mL/h/kg)** | 348 | | | | | | | | | | |
| **Vss (mL/kg)** | 1270 | | | | | | | | | | |
| **MRTinf (h)** | 3.64 | | | | | | | | | | |
| **Ratio (Lung / Plasma) @ 5 hr** | | | | - | 0.39 | - | 0.48 | - | 0.36 | | |
| **Ratio (Lung / Plasma) @ 8 hr** | | | | - | 0.51 | - | 0.49 | - | 0.47 | | |
| **Bioavailability (%)** | | 53 | NA | | | | | | | | |